• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket

    5/9/24 8:13:28 AM ET
    $AIXI
    $APP
    $ARGX
    $BVS
    Computer Software: Prepackaged Software
    Technology
    Computer Software: Programming Data Processing
    Technology
    Get the next $AIXI alert in real time by email

    Shares of AppLovin Corporation (NASDAQ:APP) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results.

    The company posted revenue of $1.058 billion, versus estimates of $974.361 million. Its earnings came in at 67 cents per share, versus expectations of 55 cents per share, according to data from Benzinga Pro.

    AppLovin shares jumped 14.8% to $85.00 in pre-market trading.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • Pop Culture Group Co., Ltd (NASDAQ:CPOP) gained 60.3% to $2.71 in pre-market trading. Pop Culture reported revenue of $24 million for the six months ended Dec. 31, 2023, up from $12.75 million in the year-ago period.
    • Sezzle Inc. (NASDAQ:SEZL) gained 36.1% to $60.87 in pre-market trading after reporting first-quarter results.
    • Inspire Veterinary Partners, Inc. (NASDAQ:IVP) shares rose 21.6% to $4.41 in pre-market trading. Inspire Veterinary Partners recently announced a 1-for-100 reverse stock split.
    • Nukkleus Inc (NASDAQ:NUKK) rose 17.7% to $1.04 in today's pre-market trading.
    • Xiao-I Corporation (NASDAQ:AIXI) shares gained 14.3% to $1.44 in pre-market trading after the company reported a strategic partnership with a leading Hong Kong Insurance Company to enhance AI-driven customer service.
    • TuanChe Limited (NASDAQ:TC) jumped 13% to $2.61 in pre-market trading.
    • Treasure Global Inc (NASDAQ:TGL) gained 12.6% to $5.35 in pre-market trading. Treasure Global is expected to report its financial results for the third quarter of fiscal year 2024, after the closing bell on Tuesday, May 14.
    • Compass, Inc. (NYSE:COMP) shares rose 12.5% to $3.69 in pre-market trading after posting first-quarter results.
    • Magnite, Inc.(NASDAQ:MGNI) shares gained 10.6% to $9.85 in pre-market trading after the company reported first-quarter financial results.

    Losers

    • Tivic Health Systems, Inc. (NASDAQ:TIVC) fell 36.7% to $0.8487 in pre-market trading. Tivic Health Systems shares jumped around 28% on Wednesday after the company announced the final results of its pilot research study on cervical vagus nerve stimulation.
    • CytomX Therapeutics, Inc. (NASDAQ:CTMX) shares declined 35.6% to $2.70 in pre-market trading after the company reported first-quarter financial results and announced initial data from the ongoing CX-904 Phase 1a dose escalation clinical study, demonstrating a favorable safety profile and confirmed anti-cancer activity.
    • Cardlytics, Inc. (NASDAQ:CDLX) shares fell 28.8% to $10.40 in pre-market trading after the company reported mixed first-quarter financial results.
    • Organovo Holdings, Inc. (NASDAQ:ONVO) fell 27.2% to $0.6969 in pre-market trading after the company priced its $5.25 million public offering of 6,562,500 common shares and common warrants at a combined price of $0.80.
    • Delta Apparel, Inc. (NYSE:DLA) fell 23.5% to $2.15 pre-market trading following weaker-than-expected second-quarter results.
    • Bioventus Inc. (NASDAQ:BVS) shares fell 20% to $4.03 in pre-market trading. Bioventus recently reported better-than-expected first-quarter financial results and raised its FY24 guidance above estimates.
    • Exact Sciences Corporation (NASDAQ:EXAS) shares declined 17.4% to $49.15 in pre-market trading after the company reported mixed first-quarter financial results.
    • Beyond Meat, Inc. (NASDAQ:BYND) shares fell 13.4% to $7.11 in pre-market trading after the company reported a wider-than-expected loss for its first quarter. The company sees second-quarter revenue to be between $85 million and $90 million and full-year 2024 revenue to be between $315 million and $345 million.
    • Duolingo, Inc. (NASDAQ:DUOL) shares declined 12.4% to $213.95 in pre-market trading after the company reported first quarter financial results.
    • argenx SE (NASDAQ:ARGX) fell 7.4% to $357.60 pre-market trading after the company reported first quarter financial results and issued a business update.

    Now Read This: Roblox, Beyond Meat And 3 Stocks To Watch Heading Into Thursday

    Get the next $AIXI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIXI
    $APP
    $ARGX
    $BVS

    CompanyDatePrice TargetRatingAnalyst
    Duolingo Inc.
    $DUOL
    3/18/2026Buy → Hold
    Argus
    CytomX Therapeutics Inc.
    $CTMX
    3/16/2026$12.00Neutral → Overweight
    Analyst
    argenx SE
    $ARGX
    3/10/2026Hold → Buy
    Deutsche Bank
    Applovin Corporation
    $APP
    3/2/2026$340.00Sell → Neutral
    Arete
    Duolingo Inc.
    $DUOL
    2/27/2026$100.00Buy → Hold
    Truist
    Duolingo Inc.
    $DUOL
    2/27/2026$100.00Buy → Neutral
    BofA Securities
    Duolingo Inc.
    $DUOL
    2/27/2026$100.00Sector Outperform → Sector Perform
    Scotiabank
    Duolingo Inc.
    $DUOL
    2/27/2026$95.00Overweight → Neutral
    Analyst
    More analyst ratings

    $AIXI
    $APP
    $ARGX
    $BVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Duolingo downgraded by Argus

    Argus downgraded Duolingo from Buy to Hold

    3/18/26 8:20:46 AM ET
    $DUOL
    Computer Software: Prepackaged Software
    Technology

    CytomX Therapeutics upgraded by Analyst with a new price target

    Analyst upgraded CytomX Therapeutics from Neutral to Overweight and set a new price target of $12.00

    3/16/26 11:34:14 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    argenx upgraded by Deutsche Bank

    Deutsche Bank upgraded argenx from Hold to Buy

    3/10/26 3:28:52 PM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIXI
    $APP
    $ARGX
    $BVS
    SEC Filings

    View All

    SEC Form 144 filed by Applovin Corporation

    144 - AppLovin Corp (0001751008) (Subject)

    3/16/26 5:37:00 PM ET
    $APP
    Computer Software: Programming Data Processing
    Technology

    SEC Form 424B5 filed by CytomX Therapeutics Inc.

    424B5 - CytomX Therapeutics, Inc. (0001501989) (Filer)

    3/16/26 4:37:02 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-K filed by Beyond Meat Inc.

    NT 10-K - BEYOND MEAT, INC. (0001655210) (Filer)

    3/16/26 4:17:35 PM ET
    $BYND
    Packaged Foods
    Consumer Staples

    $AIXI
    $APP
    $ARGX
    $BVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

    SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing of an underwritten public offering of 45,990,567 shares of its common stock at a price to the public of $5.30 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,179,245 shares of common stock. The gross proceeds to CytomX from the offering are expected to be $250 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, CytomX granted the underwriters a 30-day option to purchase up to an additiona

    3/17/26 10:46:40 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026

    The Oncodetect® test expands the role of tumor-informed MRD in triple-negative breast cancer The Cancerguard® test demonstrates improved early-stage multi-cancer detection performance Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced four presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting new data in molecular residual disease (MRD) testing and multi-cancer early detection (MCED). The meeting will take place from April 17–22, 2026, in San Diego, CA. Exact Sciences will present new findings from the NSABP B-59/GBG-96-GeparDouze trial evaluating its tumor-informed circulatin

    3/17/26 4:31:00 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Beyond Meat® Reports Delay of Annual Report on Form 10-K for the Full Year Ended December 31, 2025

    EL SEGUNDO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Beyond Meat, Inc. (NASDAQ:BYND) ("Beyond Meat" or "the Company"), a leader in plant-based meat, announced today that it will delay the filing of its Annual Report on Form 10-K for the full year ended December 31, 2025. The filing is delayed because the Company requires additional time to complete a review and analysis related to its inventory balances, including amounts recorded for the provision of excess and obsolete inventory. The Company continues to work diligently to complete its fourth quarter and full year financial close procedures and has not yet made a determination regarding the potential impact on its financial statements

    3/16/26 4:05:00 PM ET
    $BYND
    Packaged Foods
    Consumer Staples

    $AIXI
    $APP
    $ARGX
    $BVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP & CFO Singleton Mark Leonard covered exercise/tax liability with 5,865 shares and converted options into 13,500 shares, increasing direct ownership by 5% to 159,447 units (SEC Form 4)

    4 - Bioventus Inc. (0001665988) (Issuer)

    3/17/26 5:03:39 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    SVP & Chief Compliance Officer Church Katrina J converted options into 6,955 shares and covered exercise/tax liability with 3,022 shares, increasing direct ownership by 7% to 61,732 units (SEC Form 4)

    4 - Bioventus Inc. (0001665988) (Issuer)

    3/17/26 5:02:32 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    SVP & General Counsel D'Adamio Anthony converted options into 17,636 shares and covered exercise/tax liability with 7,663 shares, increasing direct ownership by 7% to 148,042 units (SEC Form 4)

    4 - Bioventus Inc. (0001665988) (Issuer)

    3/17/26 5:01:29 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $AIXI
    $APP
    $ARGX
    $BVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Shelton James H bought $498,792 worth of shares (5,000 units at $99.76), increasing direct ownership by 108% to 9,632 units (SEC Form 4)

    4 - Duolingo, Inc. (0001562088) (Issuer)

    3/4/26 4:49:44 PM ET
    $DUOL
    Computer Software: Prepackaged Software
    Technology

    Large owner Sc Capital Ii Sponsor Llc bought $2,550,000 worth of Class A ordinary shares (255,000 units at $10.00) (SEC Form 4)

    4 - Nukkleus Inc. (0001787518) (Reporting)

    12/1/25 5:20:47 PM ET
    $NUKK
    Professional Services
    Consumer Discretionary

    Director Brehm Kyle M. bought $69,978 worth of shares (1,217 units at $57.50), increasing direct ownership by 5% to 24,129 units (SEC Form 4)

    4 - Sezzle Inc. (0001662991) (Issuer)

    11/14/25 8:08:21 AM ET
    $SEZL
    Finance: Consumer Services
    Finance

    $AIXI
    $APP
    $ARGX
    $BVS
    Financials

    Live finance-specific insights

    View All

    Beyond Meat® Reports Delay of Annual Report on Form 10-K for the Full Year Ended December 31, 2025

    EL SEGUNDO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Beyond Meat, Inc. (NASDAQ:BYND) ("Beyond Meat" or "the Company"), a leader in plant-based meat, announced today that it will delay the filing of its Annual Report on Form 10-K for the full year ended December 31, 2025. The filing is delayed because the Company requires additional time to complete a review and analysis related to its inventory balances, including amounts recorded for the provision of excess and obsolete inventory. The Company continues to work diligently to complete its fourth quarter and full year financial close procedures and has not yet made a determination regarding the potential impact on its financial statements

    3/16/26 4:05:00 PM ET
    $BYND
    Packaged Foods
    Consumer Staples

    CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update

    - Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for mid-year with goal to align on potential Varseta-M registrational trial design in late line CRC - - Varseta-M Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 - - Initial CX-801 PROBODY Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 - - Company to host conference call today at 8 a.m. ET / 5 a.m. PT - SOUTH SAN FRANCISCO, Calif., M

    3/16/26 7:05:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer

    - Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - Grade 3 diarrhea rate of 10% in ongoing dose optimization cohorts - - FDA interactions targeted for mid-year with goal to align on potential registrational trial design in late-line colorectal cancer (CRC) - - Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 - - Conference call on Monday, March 16 at 8:00 a.m. ET - SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics

    3/16/26 7:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIXI
    $APP
    $ARGX
    $BVS
    Leadership Updates

    Live Leadership Updates

    View All

    Sezzle Announces Chief Financial Officer Transition

    Minneapolis, MN, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Sezzle Inc. (NASDAQ:SEZL) (Sezzle or Company) // Sezzle, a purpose-driven digital payment platform, today announced the appointment of Lee Brading as Chief Financial Officer ("CFO"), effective February 1, 2026. Brading will succeed Karen Hartje, who served as CFO and principal financial officer under a Consulting Agreement since November 1, 2025, following her announcement of retirement after nearly eight years as CFO of Sezzle. Hartje will remain engaged as a consultant to ensure an orderly transition.  "Karen has been instrumental in Sezzle's evolution from a private startup to a publicly traded, profitable fintech company," said Char

    1/29/26 4:14:17 PM ET
    $SEZL
    Finance: Consumer Services
    Finance

    Coldwell Banker Real Estate Announces 2025 Year-End Award Winners

    The brand recognizes the top affiliated sales professionals, teams, offices and companies who have demonstrated exceptional performance across multiple sales categories in the past year MADISON, N.J., Jan. 29, 2026 /PRNewswire/ -- Coldwell Banker Real Estate LLC today announced the 2025 recipients of its annual year-end awards, recognizing top‑ranking performers whose achievements exemplify the highest standards of excellence across the Coldwell Banker® network. "Each year, the dedication of the Coldwell Banker real estate professionals, teams, and offices elevates the standar

    1/29/26 10:00:00 AM ET
    $COMP
    EDP Services
    Technology

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $AIXI
    $APP
    $ARGX
    $BVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/14/24 4:26:32 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/14/24 4:00:06 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Organovo Holdings Inc.

    SC 13G - ORGANOVO HOLDINGS, INC. (0001497253) (Subject)

    11/14/24 3:34:49 PM ET
    $ONVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care